Chicago、ILにおけるリンパ腫の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、リンパ腫に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
被験者募集中第2相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
被験者募集中第3相
- Research Site, Chicago
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
被験者募集中第1相
- University of Illinois Cancer Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
被験者募集中第1/2相
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
被験者募集中第1相
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- Northwestern, Chicago
- University of Chicago, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
被験者募集中
- Northwestern University Feinberg School of Medicine, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Robert H Lurie Cancer Center, Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
被験者募集中第1/2相
- Call for Information (Investigational Site 0024), Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- Northwestern University, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
被験者募集中観察研究
- Lurie Children's Hospital-Chicago, Chicago
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
被験者募集中第1/2相
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- The University of Chicago Medical Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
被験者募集中第1/2相
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
被験者募集中
- University of Chicago Comprehensive Cancer Center, Chicago
Avo In R/R And Previously Untreated MCL
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
被験者募集中第1相
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
他の都市におけるリンパ腫の試験
- Houston, TX34件の研究
- Boston, MA33件の研究
- New York City, NY33件の研究
- Washington, DC23件の研究
- Baldwin Park, CA21件の研究
- Durham, NC17件の研究
- St. Louis, MO15件の研究
- Philadelphia, PA15件の研究
- Cleveland, OH14件の研究
- Edison, NJ12件の研究
- Atlanta, GA12件の研究
- Seattle, WA12件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。